Liquidia Shares Plummet as FDA Grants Tentative Approval, Competitor Drug Gets Exclusivity
Liquidia's shares plummeted 32% to $9.5 in premarket trading after receiving tentative approval for its PAH and PH-ILD treatment,...
Tyvaso DPI
MannKind Shares Rise After Selling Royalty Interest in Tyvaso DPI
In a major financial move, MannKind, a drugmaker, has sold part of its royalty interest in Tyvaso DPI for...
MannKind Enters Royalty Agreement for Tyvaso DPI
MannKind Corp. has entered a royalty agreement with Sagard Healthcare, where Sagard will receive 1% of royalty sales of...
MannKind Sells 1% Royalty Interest in Tyvaso DPI Sales for Up to $200 Million
MannKind, a biopharmaceutical company, has sold a 1% royalty interest in sales of the lung-disease treatment Tyvaso DPI to...